The document describes several clinical studies that evaluated the outcomes of using titanium-nitride-oxide coated stents in patients undergoing percutaneous coronary intervention (PCI). A randomized trial found that the coated stents significantly reduced late lumen loss and restenosis at 6 months compared to uncoated stents. A large registry of over 500 patients treated with the coated stents found low rates of major adverse cardiac events, target lesion revascularization, and stent thrombosis up to 1 year. The studies suggest the coated stents provide effective treatment with only short-term dual antiplatelet therapy, but direct comparison to drug-eluting stents is still needed.
Russian Call Girls in Pune Riya 9907093804 Short 1500 Night 6000 Best call gi...
Clinical outcomes TiNOX stent vs DES
1.
2. Stent Coating With Titanium-Nitride-Oxide for Reduction of Neointimal Hyperplasia in Pigs Windecker S et al. Circulation 2001;104:928-33
3. TiNOX Study Design Randomized, single-blind, multicenter trial Windecker S et al. Circulation 2005;111:2617-22 TiNOX Study N=92 Uncoated OMEGA ™ stent N=47 TiNOX coated OMEGA ™ stent N=45 R Angiographic endpoint: In-stent late lumen loss at 6 months Clinical endpoint: MACE at 30 days and 6 months
4.
5. TiNOX Study - MACE at 6 Months Windecker S et al. Circulation 2005;111:2617-22 % ns ns RR 70% P=0.006 RR 65% P=0.02
20. Titan Registry 0 1 2 3 4 Time since PCI in years 0 1 2 3 4 5 Cumulative incidence, % Incidence density 1.0 / 100 pt years 3.3% 3.5 0.6% / year 192 definite ST cases Bern-Rotterdam Cohort Study of Drug-Eluting Stents Daemen J et al. Lancet 2007;369:667-78
21.
22. Symptomatic Coronary Artery Disease Exclusion: Acute STEMI Vessel Diameters: ≥ 2.25 – ≤ 4.0 mm Stent Diameters: 2.25 – 4.0 mm Stent Lengths: 8 - 28 mm Pre-Dilatation and Post-Dilatation @ Physicians Discretion 30 d 6 mo 8 mo 12 mo 2 -5 yrs Clinical Follow-Up Primary Endpoint: In-Stent Late Loss at 8 months Key Secondary Endpoints: MACE at 30 days, 6 months, 12 months Clinically driven TLR, TVR, & TVF at 6 and 12 months Device, Lesion and Procedure Success Anti-Platelet Therapy for a minimum of 3 months ENDEAVOR n= ~150 Sites: Switzerland (3) Randomized (1:1), Single-Blind, Multi-Center Study TiNOX n= ~150 Titanium-Nitride-Oxide Coated Stents vs. Endeavor Stent